TBPH

TRELEGY ELLIPTA

Chronic obstructive pulmonary disease (COPD)

Stage (next event)

Expected Date

Quarterly Sales (Approved)

February 26, 2021 (Est)

Catalyst Info & Data Links

TITLE: TRELEGY ELLIPTA for COPD -  Quarterly Sales (Approved)


WHAT IS THE CATALYST EVENT?

  • Quarterly Sales (Approved)


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?

  • February 26, 2021 (Est)


PRIOR DATA/EVENTS

PRESS RELEASE


List last quarter's sales e.g. $$251.9M Q3/2020

2020 Revenue guidance: The Company is changing financial guidance and expects full-year 2020 operating loss, excluding share-based compensation, of $225 million to $235 million.

Mechanism of Action

MECHANISM OF ACTION

  • TRELEGY ELLIPTA contains fluticasone furoate, umeclidinium, and vilanterol. The mechanisms of action described below for the individual components apply to TRELEGY ELLIPTA. These drugs represent 3 different classes of medications (an ICS, an anticholinergic, and a LABA), each having different effects on clinical and physiological indices.

Updated by HC

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See what the community is saying - click to see full post

TBPH To Report On nOH Results For TD-9855 This Month - Medium Risk And Reward

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon